BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• Genetown

  Galecto to Participate at Upcoming Investor Conferences - Feb 07, 2022

  Galecto, Inc., a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced that management will be participating virtually at two upcoming conferences.

  February 7, 2022

   · 

  1 min read
• FDA

  NGM Bio’s NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

  NGM Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to NGM621, a monoclonal antibody product candidate engineered to potently inhibit complement C3, for the treatment of patients with geographic atrophy.

  February 7, 2022

   · 

  8 min read
• Business

  ORYZON Reports Results and Corporate Update for Q4 and Year Ended December 31, 2021

  Oryzon Genomics, S.A. today reported financial results for the fourth quarter of 2021 and provided an update on recent developments.

  February 7, 2022

   · 

  14 min read
• Pharm Country

  AEYE Health Reports Pivotal Clinical Trial Results of its AI Algorithm for the Autonomous Screening and Detection of More-Than-Mild Diabetic Retinopathy

  AEYE Health, an innovative ophthalmic technology company developing AI-based systems for the diagnosis and screening of eye diseases, is pleased to report the results from its pivotal FDA-clinical trial for the autonomous detection of more-than-mild diabetic retinopathy.

  February 7, 2022

   · 

  2 min read
• Drug Development

  Acurx Announces Publication of Positive Phase 2a Clinical Trial Results of Ibezapolstat for CDI in Clinical Infectious Diseases

  Acurx Pharmaceuticals, Inc. announced today that results of its positive Phase 2a clinical trial have been published in Clinical Infectious Diseases.

  February 7, 2022

   · 

  10 min read
• Drug Development

  Primmune Therapeutics to Present Clinical Data from Phase 1 Study Evaluating PRTX007 at the Conference on Retroviruses and Opportunistic Infections (CROI 2022)

  Primmune Therapeutics today announced that they will present data related to PRTX007, a novel, orally administered, small molecule toll-like receptor 7 (TLR7) specific agonist that is currently in Phase 1 development, at the Conference on Retroviruses.

  February 7, 2022

   · 

  1 min read
• Genetown

  Apnimed to Participate in the SVB Leerink Global Healthcare Conference

  Apnimed announced that company management will participate in 1x1 investor meetings at the SVB Leerink Global Healthcare Conference taking place virtually February 14-18, 2022.

  February 7, 2022

   · 

  2 min read
• Business

  MEI Pharma Strengthens Clinical and Quality Expertise with New Key Executive Appointments

  MEI Pharma, Inc. today announced the expansion of its management team with the addition of two experienced industry executives.

  February 7, 2022

   · 

  5 min read
• Huma.AI Adds Post-Market Surveillance Capacity to its Unique AI-Based Healthcare Data Knowledge Platform

  Company also secures $9.5 million in Series A funding to expand its resources to meet rapidly growing customer demand.

  February 7, 2022

   · 

  4 min read
• Drug Development

  Iveric Bio Announces New Post-Hoc Analyses of Zimura® from GATHER1 Clinical Trial to Be Presented at Angiogenesis, Exudation, and Degeneration 2022

  Iveric Bio Announces New Post-Hoc Analyses of Zimura ® from GATHER1 Clinical Trial to Be Presented at Angiogenesis, Exudation, and Degeneration 2022.

  February 7, 2022

   · 

  4 min read